USPTO serial 78484582
PEPLIN PHARMACEUTICALS FOR LIFE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 1, 2007
- Examiner
- JENKINS JR, CHARLES L
- Law office
- POST REGISTRATION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with PEPLIN PHARMACEUTICALS FOR LIFE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
NEWSTEAD, QUEENSLAND, AU
NEWSTEAD, QUEENSLAND, AU
NEWSTEAD, QUEENSLAND, AU
Newstead, Queensland, AU
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
JAMES F. HARRINGTON
Simor L. Moskowitz WESTERMAN HATTORI DANIELS & ADRIAN LLP1250 CONNECTICUT AVENUE, NWSUITE 700WASHINGTON, DC 20036Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Vaccines, pharmaceuticals, medical preparations, diagnostic preparations and therapeutic agents for the treatment, prevention and diagnosis of diabetes, dermatological, respiratory and/or inflammatory conditions, namely, acne, angina, arthritis, aspiration pneumonia, emphysema, gastroenteritis, intestinal flu, necrotizing enterocolitis, pelvic inflammatory disease, pharyngitis, PID, pleurisy, raw throat, redness, rubor, sore throat, stomach flu and urinary tract infections, chronic inflammatory demyelinating polyneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy; Vaccines, pharmaceuticals, medical preparations, diagnostic preparations and therapeutic agents for the treatment of cancers, namely, tumors, sarcomas, carcinomas and melanomas including tumors of the colon, breast, neck, throat, bladder, brain, liver, pancreas, adrenal glands, lymph, testicles, uterus, ovaries, lung as well solid and blood borne tumors such as ABL1 protooncogene, AIDS related cancers, acoustic neuroma, acute lymphocyte leukemia, acute myeloid leukemia,adenocystic carcinoma, adrenocrtical cancer, agnogenic myeloid metaplasia, alopecia, alveolar soft-part sarcoma, anal cancer, angio-sarcoma, aplastic anemia, astrocytoma, ataxia-telangiectasia, basal cell carcinoma, bladder cancer, bone cancers, bowel cancer, brain stem glioma, brain and CNS tumors, breast cancer, CNS tumors, carcinoid tumors, cervical cancer, childhood brain tumors, childhood cancer, childhood leukemia, childhood soft tissue sarcoma, chondrosarcoma, choriocarcinoma, chronic lymphocytic leukemia, chronic myeloid leukemia, colorectal cancers, cutaneous T-cell lymphoma, dermatofibrosarcoma-protuberans, desmoplastic-small-round-cell-tumor, ductal carcinoma, endocrine cancers, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, extra-hepatic bile duct cancer, eye cancer, fallopian tube cancer, fanconi anemia, fibrosarcoma, gall bladder cancer, gastric cancer, gastrointestinal cancers, gastrointestinal-carcinoid-tumor, genitourinary cancers, germ cell tumors, gestational-trophoblastic-disease, glioma, gynecological cancers, hematological malignancies, hairy cell leukemia, head and neck cancer, hepatocellular cancer, hereditary breast cancer, histiocytosis, Hodgkin's disease, human papillomavirus, hydatidiform mole, hypercalcemia, hypopharynx cancer, intraocular melanoma, islet cell cancer, Kaposi's sarcoma, kidney cancer, Langerhan's-cell-histiocytosis, laryngeal cancer, leiomyosarcoma, leukemia, Li-Fraumeni syndrome, lip cancer, liposarcoma, liver cancer, lung cancer, lymphedema, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, male breast cancer, malignant-rhabdoid-tumor-of-kidney, medulloblastoma, melanoma, Merkel cell cancer, mesothelioma, metastatic cancer, mouth cancer, multiple endocrine neoplasia, mycosis fungoides, myelodysplastic syndromes, myeloma, myeloproliferative disorders, nasal cancer, nasopharyngeal cancer, nephroblastoma, neuroblastoma, neurofibromatosis, Nijmegen breakage syndrome, non-melanoma skin cancer, non-small-cell-lung-cancer, ocular cancers, oesophageal cancer, oral cavity cancer, oropharynx cancer, osteosarcoma, ostomy ovarian cancer, pancreas cancer, paranasal cancer, parathyroid cancer, parotid gland cancer, penile cancer, peripheral-neuroectodermal-tumors, pituitary cancer, polycythemia vera, prostate cancer, rare-cancers-and-associated-disorders, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, Rothmund-Thomson syndrome, salivary gland cancer, schwannoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, spinal cord tumors, squamous cell carcinoma, stomach cancer, synovial sarcoma, testicular cancer, thymus cancer, thyroid cancer, transitional-cell-cancer of the bladder, transitional-cell-cancer of the renal, pelvis and ureter, trophoblastic cancer, urethral cancer, urinary system cancer, uroplakins, uterine sarcoma, uterus cancer, vaginal cancer, vulva cancer, Waldenstrom's-macroglobulinemia and Wilms' tumor | SECTION 8 - CANCELLED | — |
| 042 | Research and development, in relation to medical, biological and/or chemical diagnostic preparations, namely the identification evaluation and development of pharmaceuticals, pharmaceuticals for the treatment, prevention and diagnosis of diabetes, dermatological, respiratory and/or inflammatory conditions, namely, acne, angina, arthritis, aspiration pneumonia, emphysema, gastroenteritis, intestinal flu, necrotizing enterocolitis, pelvic inflammatory disease, pharyngitis, PID, pleurisy, raw throat, redness, rubor, sore throat, stomach flu and urinary tract infections, chronic inflammatory demyelinating polyneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy; Research and development in relation to cancers including tumors, sarcomas, carcinomas and melanomas including tumors of the colon, breast, neck, throat, bladder, brain, liver, pancreas, adrenal glands, lymph, testicles, uterus, ovaries, lung as well solid and blood borne tumors such as ABL1 protooncogene, AIDS related cancers, acoustic neuroma, acute lymphocytic leukemia, acute myeloid leukemia, adenocystic carcinoma, adrenocortical cancer, agnogenic myeloid metaplasia, alopecia, alveolar soft-part sarcoma, anal cancer, angiosarcoma, aplastic anemia, astrocytoma, ataxia-telangiectasia, basal cell carcinoma, bladder cancer, bone cancers, bowel cancer, brain stem glioma, brain and CNS tumors, breast cancer, CNS tumors, carcinoid tumors, cervical cancer, childhood brain tumors, childhood cancer, childhood leukemia, childhood soft tissue sarcoma, chondrosarcoma, choriocarcinoma, chronic lymphocytic leukemia, chronic myeloid leukemia, colorectal cancers, cutaneous T-cell lymphoma, dermatofibrosarcoma-protuberans, desmoplastic-small-round-cell-tumor, ductal carcinoma, endocrine cancers, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, extra-hepatic bile duct cancer, eye cancer, fallopian tube cancer, fanconi anemia, fibrosarcoma, gall bladder cancer, gastric cancer, gastrointestinal cancers, gastrointestinal-carcinoid-tumor, genitourinary cancers, germ cell tumors, gestational-trophoblastic-disease, glioma, gynecological cancers, hematological malignancies, hairy cell leukemia, head and neck cancer, hepatocellular cancer, hereditary breast cancer, histiocytosis, Hodgkin's disease, human papillomavirus, hydatidiform mole, hypercalcemia, hypopharynx cancer, intraocular melanoma, islet cell cancer, Kaposi's sarcoma, kidney cancer, Langerhan's-cell-histiocytosis, laryngeal cancer, leiomyosarcoma, leukemia, Li-Fraumeni syndrome, lip cancer, liposarcoma, liver cancer, lung cancer, lymphedema, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, male breast cancer, malignant-rhabdoid-tumor-of-kidney, medulloblastoma, melanoma, Merkel cell cancer, mesothelioma, metastatic cancer, mouth cancer, multiple endocrine neoplasia, mycosis fungoides, myelodysplastic syndromes, myeloma, myeloproliferative disorders, nasal cancer, nasopharyngeal cancer, nephroblastoma, neuroblastoma, neurofibromatosis, Nijmegen breakage syndrome, non-melanoma skin cancer, non-small-cell-lung-cancer, ocular cancers, oesophageal cancer, oral cavity cancer, oropharynx cancer, osteosarcoma, ostomy ovarian cancer, pancreas cancer, paranasal cancer, parathyroid cancer, parotid gland cancer, penile cancer, peripheral-neuroectodermal-tumors, pituitary cancer, polycythemia vera, prostate cancer, rare-cancers-and-associated-disorders, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, Rothmund-Thomson syndrome, salivary gland cancer, schwannoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, spinal cord tumors, squamous cell carcinoma, stomach cancer, synovial sarcoma, testicular cancer, thymus cancer, thyroid cancer, transitional-cell-cancer of the bladder, transitional-cell-cancer of the renal, pelvis, ureter, trophoblastic cancer, urethral cancer, urinary system cancer, uroplakins, uterine sarcoma, uterus cancer, vaginal cancer, vulva cancer, Waldenstrom's-macroglobulinemia and Wilms' tumor | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by PEPLIN LIMITED
- Other trademarks owned by PEPLIN LIMITED
- Other trademarks owned by PEPLIN LIMITED
- Other trademarks owned by Peplin Biotech Ltd
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named PEPLIN PHARMACEUTICALS FOR LIFE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 6, 2013 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Sep 5, 2013 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 1, 2007 | A7OK | AMENDMENT UNDER SECTION 7 - PROCESSED | — |
| Jul 12, 2007 | PLGL | ASSIGNED TO PARALEGAL | — |
| Jun 7, 2007 | AMD7 | SEC 7 REQUEST FILED | — |
| Jun 7, 2007 | PAPER RECEIVED | — | |
| May 1, 2007 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 13, 2007 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 24, 2007 | NPUB | NOTICE OF PUBLICATION | — |
| Dec 15, 2006 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 14, 2006 | ALIE | ASSIGNED TO LIE | — |
| Nov 29, 2006 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 8, 2006 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 2, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 2, 2006 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 5, 2006 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 5, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 6, 2006 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 5, 2006 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Mar 31, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 31, 2006 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 10, 2006 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jan 27, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 27, 2006 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 23, 2005 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Nov 23, 2005 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Nov 1, 2005 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 26, 2005 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 26, 2005 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 27, 2005 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 27, 2005 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 17, 2005 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 22, 2004 | NWAP | NEW APPLICATION ENTERED | — |